Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

NCT04241185 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder Neoplasms

Interventions

DRUG: Pembrolizumab
RADIATION: Conventional Radiotherapy (Bladder only)
RADIATION: Conventional Radiotherapy (Bladder and pelvic nodes)
RADIATION: Hypofractionated Radiotherapy (Bladder only)
DRUG: Cisplatin
DRUG: Fluorouracil (5-FU)
DRUG: Mitomycin C (MMC)
DRUG: Gemcitabine
DRUG: Placebo to Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC